User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer.

Primary tabs

download
  • Open access
  • PDF
  • 482.29 K
Rahier, Jean-François [UCL] Druez, Anne [UCL] Faugeras, Laurence [UCL] Martinet, Jean-Paul [UCL] Géhénot, Myriam [UCL] George, Fabienne [UCL] Delos, Monique [UCL] De Ronde, Thierry [UCL] Badaoui, Abdenor [UCL] D'Hondt, Lionel [UCL]

(eng) BACKGROUND: Colonoscopy is currently widely accepted as the gold standard for detection of colorectal cancer (CRC) providing detection of up to 95% of pre-cancerous lesions during the procedure. However, certain limitations exist in most countries including cost and access to the procedure. Moreover, colonoscopy is an invasive technique with risk inherent to the endoscopic procedure. For this reason, alternative screening tests, in particular, fecal occult blood-based tests, have been widely adopted for frontline screening. Limited compliance to colonoscopy and fecal screening approaches has prompted research on blood-based tests as an alternative approach to identifying individuals at risk who could then be referred for colonoscopy. Increased total levels of nucleosomes in the blood have been associated with tumor burden and malignancy progression. Here, we report for the first time, CRC-associated epigenetic profiles of circulating cell-free nucleosomes (cf-nucleosomes). METHODS: Levels of 12 epigenetic cf-nucleosome epitopes were measured in the sera of 58 individuals referred for endoscopic screening for CRC. RESULTS: Multivariate analysis defined an age-adjusted panel of four cf-nucleosomes that provided an AUC of 0.97 for the discrimination of CRC from healthy controls with high sensitivity at early stages (sensitivity of 75 and 86 at 90% specificity for stages I and II, respectively). A second combination of four cf-nucleosome biomarkers provided an AUC of 0.72 for the discrimination of polyps from the healthy group. CONCLUSIONS: This study suggests that a combination of different cf-nucleosome structures analyzed in serum samples by a simple ELISA is a promising approach to identify patients at risk of CRC.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2017
Language Anglais
Journal information "Clinical Epigenetics" - Vol. 9, no.1, p. 53 (2017)
Peer reviewed yes
Publisher BioMed Central Ltd. (London)
issn 1868-7075
e-issn 1868-7083
Publication status Publié
Affiliations UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - (MGD) Service de gastro-entérologie
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service d'oncologie médicale
UCL - (MGD) Autre
Keywords Blood-based screening test ; Colorectal cancer ; Epigenetics ; Nucleosomes
Links
  1. Ferlay Jacques, Soerjomataram Isabelle, Dikshit Rajesh, Eser Sultan, Mathers Colin, Rebelo Marise, Parkin Donald Maxwell, Forman David, Bray Freddie, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 : Globocan 2012, 10.1002/ijc.29210
  2. DeSantis CE, Chieh Lin C, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71.
  3. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol. 2008;103(6):1541–9.
  4. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014;146(3):709–17.
  5. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637-49.
  6. Winawer SJ, Fischer SE, Levin B. Evidence-based, reality-driven colorectal cancer screening guidelines: the critical relationship of adherence to effectiveness. JAMA. 2016;315(19):2065–6.
  7. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–502.
  8. Kedrin D, Gala MK. Genetics of the serrated pathway to colorectal cancer. Clin Transl Gastroenterol. 2015;6(4):84.
  9. Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene. 2011;30(31):3391–403.
  10. HOLDENRIEDER STEFAN, STIEBER PETRA, BODENMÜLLER HEINZ, BUSCH MARTIN, PAWEL JOACHIM, SCHALHORN ANDREAS, NAGEL DOROTHEA, SEIDEL DIETRICH, Circulating Nucleosomes in Serum, 10.1111/j.1749-6632.2001.tb03869.x
  11. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–37.
  12. Elshimali Yahya, Khaddour Husseina, Sarkissyan Marianna, Wu Yanyuan, Vadgama Jaydutt, The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients, 10.3390/ijms140918925
  13. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.
  14. Kessenbrock K, Krumbholz M, Schönermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.
  15. Summers T, Langan RC, Nissan A, et al. Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer. 2013;4(3):210–6.
  16. Jin H, Ma Y, Shen Q, et al. Circulating methylated DNA as biomarkers for cancer detection. In: Dricu A, editor. Methylation - from DNA, RNA and Histones to Diseases and Treatment. Rijeka: InTech; 2013. p. 137–52.
  17. deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55(7):1337–46.
  18. Holdenrieder S, Dharuman Y, Standop J, et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res. 2014;34(5):2357–62.
  19. Bauden M, Pamart D, Ansari D, et al. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenetics. 2015;7:106.
  20. Gezer U, Yörüker EE, Keskin M, Kulle CB, Dharuman Y, Holdenrieder S. Histone methylation marks on circulating nucleosomes as novel blood-based biomarker in colorectal cancer. Int J Mol Sci. 2015;16(12):29654–62.
  21. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/ . R Found Stat Comput Vienna, Austria. 2015:2015.
  22. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.
Bibliographic reference Rahier, Jean-François ; Druez, Anne ; Faugeras, Laurence ; Martinet, Jean-Paul ; Géhénot, Myriam ; et. al. Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer.. In: Clinical Epigenetics, Vol. 9, no.1, p. 53 (2017)
Permanent URL http://hdl.handle.net/2078.1/185414